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1. INTRODUCTION 
Chemistry is a very broad subject, and can justly claim to encompass many 
aspects of the study of biological molecules. To most researchers in the diabetic fields, 
the term ‘chemistry’ is often used in a much narrower way and is synonymous with the 
synthetic chemistry as a tool for the discovery of antidiabetic drugs. 
 
1.1.    PHARMACEUTICAL CHEMISTRY  
Pharmaceutical Chemistry is an area of chemistry that deals with the structure, 
properties and reaction of compounds that contains carbon. Chemists in general and 
organic chemists in particular can create new molecules never before proposed which, if 
carefully designed, may have important properties for the betterment of the human 
experience. One of the main objectives of organic and medicinal chemistry is the design, 
synthesis and production of molecule having value as human therapeutic agents1. 
 
The department of pharmaceutical chemistry is to impart in depth knowledge 
about all the chemical aspects of drugs and natural products, such as the structure, 
synthesis, isolation and structural activity relationship with the pharmacological activity. 
 
Medicinal chemistry 
Medicinal chemistry and bioorganic chemistry is concerned with the design, 
synthesis and analysis of the relationship between molecular structure and biological 
activity for compounds that can be used for the care or treatment of disease1. 
 
In medicinal chemistry, the chemist attempts to design and synthesis a medicine 
or pharmaceutical agent which will benefit humanity.  Such a compound could be called 
as a ‘drug’. 
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Medicinal chemistry is a part of pharmaceutical chemistry. Medicinal chemistry is 
discipline at the intersection of chemistry and pharmacology involved with designing, 
synthesizing and developing pharmaceutical drugs. Medicinal chemistry involves the 
identification, synthesis and development of new chemical entities suitable for 
therapeutic use. It also includes the study of existing drugs, their biological properties and 
their quantitative structure activity relationship (QSAR). 
 
Medicinal chemistry is the application of chemical research techniques to the 
synthesis of pharmaceuticals. During the early stages of medicinal chemistry 
development, scientist were primarily concern with the isolation of the medicinal agents 
founds in plants. Today, scientists in this field are also equally concerned with creation of 
new synthetic drug compounds. Medicinal chemistry almost always geared towards drug 
discovery and development. 
 
The first step is pharmaceutical focused on quality aspects of medicines and aims 
to assure fitness for the purpose of medicinal products. Medicinal chemistry is a highly 
interdisciplinary science combining organic chemistry with biochemistry, computational 
chemistry, pharmacology, pharmacognosy, molecular biology, statistics and physical 
chemistry. The second step of drug discovery involves the synthetic modification of the 
hits in order to improve the biological properties of the compound pharmacophore. 
 
Heterocyclic chemistry is the chemistry branch dealing exclusively with 
synthesis, properties and application of heterocyclic. Heterocyclic compound is an 
organic compound that contains a ring structure containing atom in addition to carbon, 
such as sulfur, oxygen or nitrogen as part of the ring. They may be either simple aromatic 
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or non-aromatic rings some heterocyclic compounds are known as carcinogens. 
Researchers have showed that heterocyclic amines are the Carcinogenic chemicals.    
 
A heterocyclic compound is one which possesses a cyclic structure with at least 
two different kinds of hetero atoms in the ring. Nitrogen, oxygen and sulphur are most 
common hetero atoms. Heterocyclic compounds are very widely distributed in nature and 
are essential to life in various ways. 
 
1.2. THIAZOLIDINONE 
Thiazolidin-4-one occurs as yellow crystal and odorless. It is soluble in water, 
ethanol and solvent ether. Tetra hydro derivative of thiazole ring is known as 
thiazolidine2-3. 
NH
S
O
                 
NH
S
O
                            
NH
S
O
 
5-Thiazolidinone         4-Thiazolidinone             2-Thiazolidinone 
4- thiazolidinone  and  its derivatives  have  high  pharmacological relevance  
since  they  are  available  in  both  natural  products and  pharmaceutical  compounds4-8.   
 
Method of preparation  
The number of methods for the synthesis of thiazolidinones is widely reported in 
the literature. The main synthetic routes to thiazolidin-4-ones comprising three 
components such as an amine, a carbonyl group and mercapto acid. The classical method 
of synthesis reported may be either a one-pot three-component condensation method or a 
two-step process. The reaction starts by formation of an imine which undergoes attack by 
sulfur nucleophile, followed by intramolecular cyclization to eliminate water9. 
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Kozlov co-workers10 reported a one-step cyclization reaction wherein the reaction 
of ethyl 5-phenylthioureido-3-imidazole-4-carboxylate with bromoacetic acid gives an 
imidazolylimino thiazolidin-4-one. This cyclization reaction starts by one of the nitrogen 
atom of nucleophilic centers in 5-thioureido-3-imidazole-4-carboxylic acid derivative 
yields the desired thiazolidin-4-ones11. 
+ R2 NH2R1 CHO
H2O
Et-OH
R2 N
H
R1
HS COOH
S N
O
R1
R2
 
Further, new synthetic route for the preparation of 2-isopropyl-3-benzyl-1,3-
thiazolidin-4-ones and 2-phenyl-3-isobutyl-1,3-thiazolidin-4-ones by using 1:1:3 ratio of 
valine, aldehyde and mercaptoacetic acid was reported by Cunico12et al.,., and suggested 
that the introduction of strong withdrawing group such as NO2 present in benzaldehyde 
favored the synthesis of hetero-cycle (I) in good yields, whereas the methoxy and 
fluorogroups produces the type  (II) thiazolidin-4-ones. In this connection a solvent-free 
synthesis of five-membered heterocyclic thiazolidin-4-ones from phenyl hydrazine and 
2,4-DNP as an amino moiety13. Another method of preparation of 2,3-diaryl-thiazolidin-
4-ones (III) was established, where saccharomyces cerevisiae enzyme also called as 
baker’s yeast comprising lipase was used as a catalyst in this reaction and accelerated the 
formation of imines as well as cyclo-condensation reaction of aryl aldehydes, amines 
with thioglycolic acid.  
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O
H + HO
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H3CO OCH3
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OH N
S
O
OCH3H3CO
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SH3CO
H3CO
O
+
CHO
R
+
NH2
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Saccharomyces cerevisiae
S
N
O
R
R1
R = H, OCH3, Cl, NO2, OH, 
R1 =  H, CH3 and Cl
(II)
(III)
R R
R
(I)
 
Further, the reaction of alkyl or aryl isothiocyanate (IV) with a primary amine 
furnished the corresponding thiourea derivative (V), which directly undergoes cyclization 
reaction by treating with halo acetic acid to yield two isomers of 2-imino-thiazolidin-4-
ones14(VI, VII). In addition, coupling reaction between α-chloro amide derivatives with 
an isothiocyanate in the presence of a mild base such as K2CO3 afforded the 
iminothiazolidin-4-one derivatives15 (VIII).  
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Mechanism of reaction for the preparation of Thiazolidinones 
The reaction between substituted thiourea with acid to haloacetic acid produces 2-
iminothiazolidin-4-ones. These reactions occur in polar solvents such as ethyl alcohol 
under reflux and in the presence sodium acetate or pyridine16. Substituted thiourea can be 
procured by a reaction with primary amines. Thiourea undergoes asymmetric reactions 
and form two regioisomers, where the regioselectivity is controlled by electronic factors, 
especially the combination of electron-withdrawing substituent (aryl or heteroaryl) with 
nitrogen imino group17.  
 
R1NH NHR2
S
+ X OR
O
S N
O
R1
N R2
+ S N
O
R2
N R1
Thiourea
R1 = Aryl or Heteroaryl
R2 = Alkyl
X = Br or Cl
R = H, CH3 or C2H5
Mechanism
R1NH NHR2
S
R1N NHR2
SH X OR
O
S NH
OR
O
N
R1
R2
H
X
S N
O
R1
N R2
OR
H
-HX
S N
O
H
N R2
S N
O
R1
N R2
R1
OR
-ROH
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Properties of 4-thiazolidinones 
The 4-thiazolidinones are generally solid forms, often melting with decomposition 
but the attachment of alkyl group with the nitrogen minimizes the melting point. The aryl 
or higher alkyl substituent’s of 4-thiazolidinone slightly soluble in water.   
 
Chemical properties of 4-thiazolidinones 
The structure of 4-thiazolidinones exists in the literatures18. 4-Thiazolidinones are 
the derivatives of thiazolidine with C=O group at fourth position19. Substitution of 
various groups at 2nd, 4th and 5th position is possible. A different optical isomeric form of 
thiazolidinone is reported in the references20 and number of regioselective isomers has 
been reported21,22. The C=O group of thiazolidin-4-one is highly inert nature. But in few 
cases thiazolidin-4-one on reaction with Lawesson’s reagent gives corresponding 
thiazolidin-4-ones23. Tautomer of 2-iminothiazolidine-4-one found to exhibit some 
chemical interest. 
 
Several methods are available in order to synthesis a thiazolidin-4-ones in the 
literatures24 which involve conventional, microwave irradiation method and 
combinatorial synthesis. The reaction between NH2 with CS2 in the presence of alkali 
which then reacts with haloalkanoic acid in the presence of Na2CO3 yields thiazolidin-4-
ones. 
 
Among the various reactions involving the thiazolidin-4-one ring, reactions 
occurring at first position (sulfur) in the oxidation reaction25, third position (nitrogen) in 
N–alkylation reaction26 and mannich reaction27, fourth position (C=O) in thionation 
reaction via Lawesson's reagent28 and fifth position (CH2) in condensation reaction with 
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aldehydes and ketones or diazonium salts29 is processed. Here by all the above reactions 
are disussed in detail. 
NHS
O
 
 
N–alkylation reaction 
Nishimoto and co-workers30 found that thiazolidin-4-ones substituted in the 
second position with alkyl or alkoxy groups undergo an N-alkylation reaction. In this 
method, equivalent amount of potassium hydroxide was used with thiazolidin-4-ones in 
anhydrous DMF which promotes the formation of amide anion through the abstraction of 
hydrogen at N-3 position and subsequent attack of this anion with 1, 2-dibromoethane at 
room temperature. The use of potassium hydroxide is essential for the formation of amide 
anion, since thiazolidin-4-one unsubstituted in third position are weak acids. 
S NH
O
R
KOH / DMF
BrCH2CH2 Br
S N
O
R
Br
N-2-bromoethyl-4-thiazolidinone
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Mannich reaction 
Mannich reactions are generally occurring between 2-iminothiazolidin-4-ones and 
NH2 or NH in presence of formaldehyde or paraformaldehyde in methyl alcohol to 
produce 2-imino-3-(substituted amino methyl) thiazolidin-4-one31.  
S NH
O
N R
+
R1NH2
    or
R2NH2
HCHO /CH3OH S N
O
N R
CH2NHR1 or S N
O
N R
CH2NHR2
2-imino-3-aminoalkyl /aryl- 4-thiazolidinone
2-imino-4-thiazolidinone
 
 
 
Condensation reaction with aldehydes 
The CH2 group at fifth position of thiazolidin-4-one ring due to its acidity it 
undergoes condensation reaction with aldehydes or ketones in knoevenagel reaction32. In 
this reaction, formation of an enolate intermediate is stabilized, which is more dependent 
on the electron attractive effect of the C=O group adjacent to the CH2 group and the 
presence of electron-attractive group at second position of thiazolidin-4-one ring33. The 
condensation reaction typically occurs in presence of glacial acetic acid and sodium 
acetate where sodium acetate functions as both alkali and as well as a dehydrating agent 
in piperidine solution or ethanol34. 
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S NH
O
N R
+ Ar-CHO
CH3CO2Na /
CH3COOH
or
Pyridine / EtOH
   reflux
S NH
O
N R
HC
Ar
2-imino-4-thiazolidinone
2-imino-5-arylidene-4-thiazolidinone
 
ANTIDIABETIC ACTIVITY 
4-Thiazolidinones are used mainly as anticoagulant and anti-thrombic agents in 
therapy. Over the past two decades, literatures related to the effects of thiazolidinones are 
used and their derivatives on diabetes and its complications are reported. The search for 
new thiazolidinones against diabetes and its complications, either isolated from 
traditional medicine or chemically synthesized, has been constantly expanding. The 
cellular and molecular mechanisms include protecting pancreatic beta cells from damage, 
improving abnormal insulin signaling, reducing oxidative stress/inflammation, activating 
AMP-activated protein kinase (AMPK), inhibiting α-amylase and α-glucosidases34.  
 
DIABETES MELLITUS 
Diabetes Mellitus is a metabolic disorder characterized by the presence of chronic 
hyperglycemia accompanied by greater or lesser impairment in the metabolism of 
carbohydrates, lipids and proteins. Etiology of Diabetes Mellitus includes defect in either 
insulin secretion or response or in both at some point in the course of disease. Mostly 
patients with diabetes mellitus have either Type 1 diabetes (which is immune-mediated or 
idiopathic) Type 2 Diabetes Mellitus (formerly known as non-insulin dependent Diabetes 
Mellitus) are the most common forms of Diabetes Mellitus which is characterized by 
hyperglycemia, insulin resistance, and relative insulin deficiency36. 
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Type 2 Diabetes Mellitus results from interaction between genetic, environmental, 
behavioural factors37,38, and also includes gestational hormonal environment, genetic 
defects, other infections, and even due to certain drugs. The worldwide prevalence of 
diabetes has continued to increase dramatically. Globally, as of 2011, an estimated 366 
million people had Diabetes Mellitus, with Type 2 making up about 90% of the cases39,40. 
The number of people with Type 2 Diabetes Mellitus is increasing in every country and 
80% of the people living in low- and middle-income countries. The treatment goal of 
diabetic patients is to maintain near normal levels of glycemic control, in both fasting and 
post-prandial conditions. 
 
Globally, an estimated 422 million adults were living with diabetes in 2014, 
compared to 108 million in 1980. The percentage of deaths attributable to high blood 
glucose or diabetes that occurs prior to age 70 were higher in low- and middle-income 
countries than in high-income countries(WHO,2016). The maximum number of diabetic 
patients was recorded in India followed by china and USA. If the current condition 
prevails and nothing much is done in future, then by the year 2030, number of individuals 
affected by diabetes in India would raise up to 79 million. 
 
CLASSIFICATION OF DIABETES MELLITUS 
The classification of Diabetes Mellitus was based on etiological factors of the 
diseases. The old and confusing terms of insulin-dependent (IDDM) or non-insulin-
dependent (NIDDM) which were proposed by WHO in1980 and 1985 have disappeared 
and the terms of new classification system identifies four types of diabetes mellitus: Type 
1, Type 2, gestational diabetes and Monogenic diabetes. 
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TYPE 1 DIABETES MELLITUS 
Type 1 diabetes mellitus (juvenile diabetes) is characterized by beta cell 
destruction caused by an autoimmune process, usually leading to absolute insulin 
deficiency. Type 1 is usually characterized by the presence of anti–glutamic acid 
decarboxylase and islet cell or insulin antibodies which identify the autoimmune 
processes that lead to beta cell destruction. Eventually, all Type1 diabetic patients will 
require insulin therapy to maintain normoglycemia. 
TYPE 2 DIABETES MELLITUS 
The relative defects in insulin secretion or in the exhibit intra-abdominal 
(visceral) obesity, which is closely related peripheral action of the hormone in the 
occurrence of Type 2 diabetes. This is the most common form of diabetes mellitus and is 
highly associated with family history of diabetes, older age, obesity and lack of exercise. 
Type 2 diabetes comprises 80% to 90% of all cases of Diabetes mellitus. Most 
individuals with Type 2 diabetes will be having insulin resistance,  hypertension and 
dyslipidemia (high triglyceride and low HDL-cholesterol levels; postprandial 
hyperlipidemia) often present in the individuals. It is more common in women, especially 
women with a history of gestational diabetes, and in Blacks, Hispanics and Native 
Americans. 
 
 
GESTATIONAL DIABETES MELLITUS (GDM) 
Gestational diabetes mellitus is an operational classification (rather than a 
pathophysiologic condition) in which women who develop diabetes mellitus during 
gestation. Women who develop Type 1 diabetes mellitus during pregnancy and women 
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with undiagnosed asymptomatic Type 2 diabetes mellitus that is discovered during 
pregnancy are classified as Gestational Diabetes Mellitus (GDM). In most women who 
develop GDM; the disorder has its onset in the third trimester of pregnancy. 
 
OTHER SPECIFIC TYPE (MONOGENIC DIABETES) 
Types of diabetes mellitus of various known etiologies are grouped together to 
form the classifycation called “Other Specific Types”. This group includes persons with 
genetic defects of beta-cell function (this type of diabetes was formerly called MODY or 
maturity-onset diabetes in youth) or with defects of insulin action; persons with diseases 
of the exocrine pancreas, such as pancreatitis or cystic fibrosis; persons with dysfunction 
associated with other endocrinopathies (e.g. acromegaly); and persons with pancreatic 
dysfunction caused by drugs, chemicals or infections and they comprise less than 10% of 
Diabetes Mellitus cases. 
 
Importance of α-Amylase Enzyme in the Body 
In humans, the digestion of starch involves several stages. Initially, partial 
digestion by saliva results in the degradation of polymeric substrates into shorter 
oligomers. Later on in the gut these are further hydrolyzed by pancreatic α-amylase into 
maltose, maltotriose and small malto-oligosaccharides. The digestive enzyme (α-
amylase) is responsible for hydrolysing dietary starch (maltose), which breaks down into 
glucose prior to absorption. Inhibition of α-amylase can lead to reduction in post-prandial 
hyperglycemia in diabetic condition. 
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Importance of α-Glucosidase Enzyme in the Body 
α-glucosidase is a membrane bound enzyme located on the epithelium of the 
small intestine, catalysing the cleavage of disaccharides to form glucose. Inhibitors can 
retard the uptake of dietary carbohydrates and suppress post-prandial hyperglycemia. 
Therefore, inhibition of α-glucosidase could be one of the most effective approaches to 
control diabetes. Glucosidases are not only essential to carbohydrates digestion, but also 
vital for the processing of glycoprotein and glycolipids. This enzyme is a target for 
antiviral agents that interfere with the formation of essential glycoproteins required in 
viral assembly, secretion and infection. Glucosidase are also involved in a variety of 
metabolic disorders and carcinogenesis41,42. 
 
ENZYMES43 
Enzymes are proteins, macromolecules they catalyse the chemical reactions in 
biological systems. They are specific in nature. 
There are three different types of enzymes in human body, they are. 
 
1) Metabolic enzymes 
They are the spark of life, the energy of life, and the vitality of life. In human 
body every biochemical reactions that occurs are catalyst and regulated by enzymes only 
and making them essential to cellular functions and health. 
2) Food enzymes 
By consumption of supplemental enzyme products and through the raw foods we 
eat these food enzymes get into the body. Raw foods are the source of digestive enzymes 
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when ingested. However raw food manifest only enough enzymes to digest the particular 
food, not enough to be stored in the body for the later use.  
 
 
3) Digestive enzymes 
Helps in digesting the food and the nutrients in the food are delivered to different 
parts of the body. The most important digestive enzymes are a) Proteases (split proteins 
into their monomers, the amino acids), b) Lipases (split fat into free acids and glycerol 
molecules), carbohydrates (split carbohydrates such as starch and sugar into sample 
sugars such as glucose) and d) Nucleases (split nucleic acid into nucleotides).In which α-
amylase is one of the digestive enzyme since it begins its process by digesting the starch 
and breaks them into smaller pieces with two or three glucose units. 
 
α – Amylase44-45 
α- amylase is found in the saliva, pancreatic secretions, and in the gastrointestinal 
tract. It severs an obvious role in polysaccharide digestion. α-amylase determination has 
been recognized as an important role for the diagnosis of diabetes for many years because 
elevated levels of the enzyme are associated with liver and pancreatic disorders. 
 
The structure of starch consists of glucose polymers linked by α-1,4 and α-1,6 
glycosidic bonds. α-amylase is an enzyme that catalyses the hydrolysis of starch into 
sugar. Amylase hydrolyse internal α-1,4- glucosidic linkage in starch. Largely at random, 
to produce dextrins and disaccharides.  
1.INTRODUCTION  
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 28 
      Strach (insoluble) 
    
 α-amylase 
 
Dextrins 
      α-amylase 
 
Disaccharides 
      α – glucosidase 
 
Monosaccharide glucose 
 
 
Readily absorbed in GIT 
 
 
Blood stream glucose level increases 
 
First α-amylase degrade starch into dextrin’s and then to maltose by hydrolyzing 
α-1,4 glucan bonds. In digestion, the primary role of α- amylase is to perform the first 
reaction of this process, generating dextrin’s that are subsequently hydrolyzed by other 
enzymes. This will comes under the classification of carbohydrates. 
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Starch 
Starch is the most important dietary source for humans. High content of starch is 
found in cereals, roots, tubers etc. Starch is a homopolymer composed of D- Glucose 
units held by α-glycosidic bonds. It is known as glucosan or glucan. Starch consists of 
two polysaccharide components – water soluble amylase and a water insoluble 
amylopectin. Chemically amylase is a long unbranched chain with 200- 1000 D-glucose 
units held by α-1,4- glycosidic linkages. 
Amylopectin, on the other hand, is a branched chain with α-1,6 glucosidic 
linkages at the branching points and α-1,4 linkage in the other place. Amylopectin 
molecule, which is composed of a few thousand glucose units, looks like a branched tree 
with 20-30 glucose units/ branch. 
 
Enzyme inhibitors [30] 
The molecules which bind to enzymes and decrease their activity are termed as 
Enzyme inhibitors. Many drugs are enzyme inhibitors, since it can block an enzyme 
activity and correct a metabolic imbalance. Some of the enzyme inhibitors are also 
herbicides and pesticides. Not all molecules that bind to enzymes are inhibitors. There are 
also enzyme activators that bind to the enzyme it enhance the enzymatic activity, while 
enzymes substrates bind and are converted to products in the normal catalytic cycle of the 
enzyme. 
 
The binding of an inhibitor can stop a substrate from entering the enzymes‟s 
active site and/ or hinder the enzyme from catalysing its reaction. In the past the only way 
to discover these new inhibitors was by trial and error. This brute force approach is still 
successful and has even been extended by combinatorial chemistry approaches that 
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quickly produce large number of novel compounds and high- throughput screening 
technology to rapidly screen these huge chemical libraries for useful inhibitors. 
 
α-Amylase Inhibitors[31]  
The activity of α-amylase is reported to be inhibited incase of diabetes. Therefore 
these- amylase inhibitors are acting as anti-diabetic drugs that work by preventing the 
digestion of carbohydrates. 
The inhibition of α- amylase is by, 
 
Metal chelators, organic acids and heavy inorganic metal ions: 
All metal chelators are strong inhibitors of amylase as they are metalloenzymes. 
Eg. EDTA, of the organic acids, citric acid and oxalic acid is found to be the most potent 
inhibitor of amylase. Heavy metal ions such as Al3+, Fe2+, and Hg2+ are known to inhibit 
amylase at higher concentration. 
 
Crude plant extracts:  
A number of crude plants extracts have been reported to have α- amylase 
inhibitory activity by many researchers. Some of the plant species like Murraya koenigii 
and Ocimum tenuiflorum extracts of which are reported to have appreciable α- amylase 
inhibitory activity. 
 
Pure natural products:  
A synthetic pseudotetrasaccharide, Acarbose originally isolated from 
microorganisms, is an established inhibitor of both α- amylase and α- glucosidase. 
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ACARBOSE 
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Pharmaceutical significance of α- amylase inhibitors: 
α- amylase inhibitors inhibit the digestion and the production of glucose from 
complex polysaccharides. These inhibitors have the potential to supress post prandial 
blood glucose level in diabetic patients. Acarbose which lower blood glucose by 
inhibiting α- amylase and α- glucosidases is currently used as an antidiabetic drug. 
Tendamistat (produced by stretomyces tendae and stretomyces lividans) is an 
extracellular polypeptide containing 74 amino acids, which showed significant biological 
activity similar to α- amylase inhibitor and it has been shown to have significant 
application in the treatment of diabetes mellitus. Due to its resistance against most 
hydrolytic enzymes, tendamistat would be orally available for the treatment of diabetes 
mellitus. Adiposin-1 (isolated from Streptomyces calvus) inhibits human α- amylase, is 
another example of potential antidiabetic compounds obtained from microbes. 
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2. REVIEW OF LITERATURE  
Various 4-thiazolidinone derivatives have been developed by structural 
modifications in order to enhance the biological properties such as anticonvulsant, anti-
cancer, CNS depressant, analgesic, anti-inflammatory, etc. Herein a detailed literature 
survey is described for 4-thiazolidinone derivatives. 
 
2.1. ANTIDIABETIC ACTIVITY 
Pattan and co-workers46 in the year 2005 reported the synthesis and anti-diabetic 
activity of 2-amino [5(-4–sulfonylbenzylidine)-2,4-thiazolidindione]-7-chloro–6 - 
flurobenzothiazole. The synthesized compounds were found to possess potent anti-
diabetic activity. 
 
  In the year 2009, Firake BM and co-workers47 reported the synthesis of series of 
N-ary/alkyl substituted pyridine thiazolidinones (1). These compounds were screened for 
their antidiabetic activity on wistar-strain rats and acute toxicity. All the tested 
compounds were found to possess good antidiabetic activity. 
SN
O
NHNOCH2CO
R
 
(1) 
Suroor Ahmad Khan and co-workers48 in the same year have prepared a series of 
2-substituted phenyl-3-(1-naphthyl)-1,3-thiazolyl-amino-4-oxo thiazolidin acetic acid 
derivatives and evaluated their anti-hyperglycemic activity. The bioactivity results 
revealed that all compounds possess more potent antihyperglycemic activity. 
 
In the year 2010, Vipan Kamboj and co-workers49 synthesized a series of 3-(4-
alkyl/arylsubstituted)-4-oxo-1,3-thiazolidin-2-ylidene acetohydrazide (2). All the 
compounds were screened for their antidiabetic activity. Among the tested compounds, 
the compound 3-phenyl substituted-4–oxo-1,3-thiazolidin-2-ylidene acetohydrazide 
possess high activity with reduced toxicity.  
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(2) 
Synthesis of 5-substituted-4-thiazolidinones (3) as anti-hyperglycemic activity 
was reported by Birendra Srivastava and co-workers50 in the year 2010. These 
compounds were found to possess good anti-hyperglycemic activity.  
N
S
NH N
S
O
Ar
H3C
 
(3) 
Deepthi Kini and co-workers51 in the year 2011 reported the synthesis of new 
series of 3-(5-methyl-2-aryl-3-thiazolylamino)-4- thiazolidinone coumarin derivatives. 
The prepared compounds have been evaluated for their oral hypoglycemic activity. 
Among the tested compounds, the compound 3-(5-methyl-3-(4-nitrophenyl)-3-
thiazolylamino-4-thiazolidinone coumarin exhibited high profile of activity when 
compared to standard. 
 
2.3. ANTI-VIRAL ACTIVITY 
FaridBadria and co-workers52 in the year 2003 synthesized a new thiazolidinone 
and oxadiazoline coumarin (4) derivatives and investigated their antiviral activity, 
cytotoxicity and SAR studies. All compounds were found to exhibits high antiviral 
profiles. 
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(4) 
Synthesis of benzimidazole and thiazolidinone derivative (5) as HIV-1 RT 
inhibitors by microwave irradiation technique was reported by Anna Maria Monforteet 
al.,53 in the year 2004. Among the evaluated compounds the compound 2-(2,6-
difluorophenyl)-3-(3-methoxyphenyl)-1,3-thiazolidin-4-one emerged as potent HIV-1 
with marked RT inhibitory affects. 
N
S
O
X
Y
R3
R4
R5
R1
R2
 
(5) 
Zappala and co-workers54 in the year 2004 synthesized 1,3-thiazolidinones with 
dihalogen and pyrimidine substitution. The prepared compounds were screened for their 
HIV-1 reverse transcriptase enzyme inhibition studies. From the activity data it was 
found that all the compounds were found to possess good HIV-1 activity.      
In the year 2005, DharmarajanSriram and co-workers55 reported the synthesis and 
anti-YFV activity of 2, 3-diaryl-1,3-thiazolidin-4-ones (6) by microwave-assisted 
reaction. The synthesized compounds were evaluated for their inhibitory effects on the 
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replication of YFV in green monkey kidney (Vero) cells (ATCC CCL81), by means of a 
cytopathic effect reduction assay. 
N
S
Ar
O
R
 
(6) 
Ravindra K Rawal and coworker56 in the year 2007 reported molecular docking 
studies of 4-thiazolidinones as HIV-1 RT inhibitors. The docking studies provided an 
insight into the pharmacophoric structural requirements for the HIV-1 RT inhibitory 
activity of this class of molecules. 
 
In the year 2011, RavichandranVeerasamy and co-workers57 has reported the 
design, synthesis and biological evaluation of thiazolidinone derivatives as potent anti-
viral agents. All the compounds possessed high degree of antiviral potential. 
 
2.4. ANTIMYCOBACTERIAL AND ANTIFUNGAL ACTIVITY 
EvelinBoshra and co-workers58 in the year 1989 reported some new heterocyclic 
thiazolidines (7) with acaricidal, insecticidal and bactericidal activity. The reported 
compounds were found to possess cgood bactericidal and inseticidal activities. 
S
N
O
COOHS
H3C CH3
O
O
 
(7) 
In the year 1990, HamedEad and co-workers59 reported a cycloaddition reaction 
of series of 5-(2-thienyl) methylene (8) derivatives of thiazolidinone-4-thiones. The 
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synthesized compounds were screened for antimicrobial activities. The results of 
biological activity expressed that all compounds were more potent in nature. 
S
S
S N
X
R
COOMeCOOMe
 
(8) 
 Preparation of quinoxaline derivatives containing thiazolidinone (9) residue as a 
potent antibacteial and antifungal agent was reported by Afaf K Ansary and co-workers60 
in the year 1995. All the compounds were found to exhibit significant antimicrobial 
activity. 
N
N
CH2CONH
CH3
O
N
S
O
NH
 
(9) 
Sayed R and co-workers61 in the year 1999 synthesized a novel compound 2-[2-
carboxymethylthio-2-(4-chlorophenyl) ethyl]-2-(4-chlorophenyl)-4-thiazolidinone (10) 
and studied its biological potency.  
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(10) 
  
 
ANTICANCER ACTIVITY 
Monforte and co-workers62 in the year 1988 reported the antitumor activity of 
series of 2-alkyl-[2-(1, 3, 4-thiadiazolyl)]-4-thiazolidinones. These compounds were 
tested against the leukemic 388 tumor system. All the compounds were found to 
exhibited significant antitumor activity. 
 
Duane D Miller and co-workers63 in the year 2004 reported the synthesis, SAR 
and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides (11) for prostate 
cancer. From this study, three potent compounds have been detected, which were 
effective in killing prostate cancer cells with improved selectivity.   
S
N
O
R
O
R'
 
(11) 
Roman Lesyk and co-workers64 in the same year have reported some novel 4-
thiazolidones (12) derivatives and studied their anti-diabetic (insulin-sensitizing), aldose 
reductase, thyromimetic, antimicrobial, antiviral, anti-ischemic, cardiovascular and 
anticancer activity. 
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(12) 
In the year 2005, StefaniaCarotti and co-workers65 reported in-vitro anti-
proliferative activity of 4-thiazolidinones against human colon cancer cell lines. The 2-
phenylimino and 2,4-thiazolidinone (13) derivatives were found to be the most active 
compounds. 2-Phenylimino derivative inhibits the HT 29 cell line by a high COX-2 
expression and 2,4-thiazolidinones inhibits all cell lines.  
N
S
O
O
H
F3C
H
 
(13) 
Amany Sayed Maghraby and co-workers66 in the year 2005 reported the synthesis 
of series of new 4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine (14) derivatives 
incorporated thiazolidinone moiety. The synthesized compounds were tested for possible 
serine prostate and cercarialelastase inhibitory effects with a possible prospective to 
block penetration of schistosomamansonicercariae in to the skin. 
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(14) 
Benaka Prasad and co-workers67 in the year 2008 synthesized a series of novel 5-
(4-methyl benzylidene)-thiazolidine-2,4-dione (15) derivatives with different substituted 
aromatic sulfonyl chlorides and alkyl halides. The synthesized compounds were 
evaluated for their cell antiproliferative activity by MTT assay. The nitro group in the 4th 
position on aryl ring plays a dominant role and was responsible for the antiproliferative 
activity.  
N
S
O
O R
H3C
 
(15) 
Shuhong Wu and co-workers68 in the year 2008 reported the synthesis of 
pharmacophore of thiazolidinone derivatives. The synthesized compounds were 
evaluated for their structure activity relationship, cytoselective toxicity and anti-cancer 
activity.   
 
In the year 2009 Rosanna Maccari and co-workers69 synthesized 4-(5-arylidene-4-
oxo-2-phenylimino thiazolidin-3yl)-methyl benzoic acids (16) and screened their 
inhibitory activity against human PTP1b and LMW-PTP enzymes. Among the evaluated 
compounds, the 5-arylidene substituted moiety proved the potency. 
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(16) 
 In the same year, Zimenkovsky and co-workers70 have synthesized a novel 
nonfused bicyclic thiazolidinones. These compounds were screened for their anticancer 
activity. Among the tested compounds, the compound 2-(4-oxo-3-furyl methyl-4-
oxothiazolidin-5-yl-N-4-chlorophenyl) acetamide was found to be more potent anticancer 
agent than the standard compound. 
 
Havrylyuk Dmytro and co-workers71 in the year 2010 reported the synthesis and 
anticancer activity evaluation of 4-thiazolidinones (17) containing benzothiazole moiety. 
These compounds were screened for in-vitro anticancer activity. The activity data 
exhibits that all compounds were found to show potent anticancer activity. 
S
N
O
COOH
N
 
(17) 
Kaminskyy DV and co-workers72 in the year 2010 described the structure–
anticancer activity relationships among 4-thiazolidinone-3-carboxylic acids derivatives. 
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In the year 2010, IvannaSubtelna and co-workers73 synthesized the 5-arylidene-2-
amino-4-thiazolones (18) and evaluated their anticancer activity. The synthesized 
compounds were found to possess a good anticancer activity. Among the tested one, the 
compounds 5-(4-chlorobenzylidene)-2-(4- hydroxyl phenyl amino) thiazol-4-one and 5-
(2-chloro-3-(4-nitrophenyl)-2-propenylidene)-2-(3-hydroxyphenylamino) thiazol-4-one 
were found to possess high effect on all leukemia cell lines.  
N
N
H
NH
Ar
O
R3
 
(18) 
In the year 2011 Maity TK and co-workers74 reported the synthesis, 
characterization and antiproliferative activity of 2-(substituted phenyl)-5-methyl-3-
pyridin-4yl-1,3-thiazolidinones. These compounds were evaluated for in-vitro 
cytotoxicity against lymphoma cancer cell lines at varies concentrations. Among the 
tested compounds, two compounds showed highest cytotoxic activity against L929 cell 
lines. 
A series of regioselective 3-thiazolidine acetic acid derivatives were synthesized 
by Zhengming Li and co-workers75 in the year 2011. These compounds were evaluated 
for anti-tumor activity. The results of bioactivity data showed that modification at the C-
H of amino acid, N-(per-o-acetyl glycosyl amino) thioxo methyl) ethyl ester results in 
great influence on anti-tumor activity. 
 
 Ping Gong and co-workers76 in the year 2012 reported the design and synthesis of 
2-iminothiazolidin-4-one moiety-containing compounds as potent antiproliferative 
agents. The Pharmacological data indicated that most of the compounds possessed 
moderate activity, some showed remarkable activity.  
 
2.5. ANTICONVULSANT ACTIVITY 
In the year 1996, Ulusoy and co-workers77 have reported the synthesis, 
characterization and anticonvulsant evaluation of bis-thiazolidin-4-one (19). The results 
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of biological activity indicate that substitution of phenyl group at 3rd position and alkyl 
group at 4th position results in potent activity. 
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(19) 
Aysel and co-workers78 in 2005 have synthesized and isolated a new series of 2,3-
regioisomeric substituted-4-thiazolidinones (20). These compounds were screened for 
their anticonvulsant activity. The anticonvulsant data showed that substitution at 3rd 
position favors pronounced activity. These compounds were found to possess good 
anticonvulsant activity. 
N
N
O
S
O
NH
N
S
N
R
O
 
(20) 
Kailash and co-workers79 in the year 2007 reported the new series of triazole 
substituted thiazolidinone derivatives (21). These compounds were evaluated for their 
neurotoxicity and anticonvulsant activity in two animal models of seizures. The results of 
screening data shown that, three compounds exhibited excellent anticonvulsant activity. 
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Huger and coworkes80 in the year 2010 have synthesized a group of 
thiazolidinones containing 2-mercapto benzimidazole moiety (22) and screened them for 
in-vivoanticonvulsant activity by maximal electroshock (MES) model. The activity data 
reveals that all the synthesized compounds were found to possess potent anticonvulsant 
activity. 
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(22) 
In the same year synthesis and anticonvulsant activity of novel substituted 
thiadiazolylazetidinonyl derivatives (23) were reported by Saxena and co-workers81. The 
activity data concludes that among the synthesized compounds, some of the title 
compounds exhibited promising anticonvulsant activity. 
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(23) 
Rangappa and co-workers82 in the same year reported synthesis of group of 
thiazolidin-4-ones and 1,3,4-oxadiazoles containing mercapto benzimidazoles (24). The 
synthesized compounds were screened for in-vivo anticonvulsant activity by MES model 
and antidiabetic activity. All the compounds were exhibited potent anticonvulsant and 
antidiabetic activities. 
N
H
N
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(24) 
In the year 2011, Ganesh Akula and co-workers83 prepared a series of benzimidazolyl 
amino thiazolidin-4-ones (25). These   compounds were screened for anticonvulsant 
activity by the MES induced seizure model. All the compounds were significantly 
showed their anticonvulsant activity similar to that of standard. 
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(25) 
Tejprakash and co-workers84 in the same year have synthesized and characterized 
a series of substituted 5-ethylidene-2-phenylimino-4-thiazolidinones (26). These 
compounds were screened for their anticonvulsant activity. From the results they 
concluded that substitution in 5th position with electrophilic groups such as nitro group 
shows good anticonvulsant activity than the nucloephilic groups such as methoxy and 
methyl group. 
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26) 
Nikalje and co-workers85 in the same year reported a series of 2-dioxoisoindolin-
N-4-oxo substituted thiazolidinylacetamide derivatives (27). All the compounds were 
evaluated for anticonvulsant and CNS depressant activity in mice by MES and 
pentylenetetrazole induced seizure model and also screened their neurotoxicity. The 
results reveals that all the compounds were showed protection against MES test to inhibit 
seizure. 
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(27) 
 
In the year 2012, Indulathaet al. 86 have reported the synthesis of novel N-4-oxo-
2-aryl and heteroaryl substituted thiazolidin-3-yl-3-carboxamido-2H-chromen-2-ones 
(28) as potent anticonvulsant agents. The activity results indicated that all the compounds 
exhibited 63 percent protection which is an indicative of having ability to prevent seizure 
spread at the dose level of 100 mg/kg when compared to the standard drug. 
 
(28) 
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O
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3. RESEARCH ENVISAGED 
 
AIM OF THE STUDY 
Diabetes mellitus is a major endocrine disorder affecting nearly 10% of the 
population all over the world. It is characterized by hyperglycemia and disturbances 
of carbohydrate, protein and fat metabolisms, secondary to an absolute or relative 
lack of the hormone insulin. The number of people in the world with diabetes has 
increased dramatically over recent years. It is also predicted that by 2030, India, 
China and the United States will have the largest number of people with diabetes. 
Currently treatment of diabetes, in addition to insulin supplement includes many oral 
hypoglycemic agents along with appropriate diet and exercise. The treatment goal of 
diabetic patients is to maintain near normal levels of glycemic control, in both fasting 
and post-prandial conditions. 
 
Postprandial hyperglycemia has been proposed as an independent risk factor 
for diabetes mellitus. Therefore, control of postprandial hyperglycemia is suggested 
to be important in the treatment of diabetes. One of the effective method to control 
diabetes is to inhibit the activity of α-amylase enzyme which is responsible for the 
breakdown of starch to more simple sugars(dextrin, maltotriose, maltose, and 
glucose). This is contributed by α-amylase inhibitors, which delays the glucose 
absorption rate thereby maintaining the serum blood glucose in hyperglycemic 
individuals. This study is focused to investigate the inhibitory potentials of the 
synthesized thiazolidinone derivatives on α-amylase, the key enzyme responsible for 
carbohydrate hydrolysis. 
 
4-thiazolidinone possess a wide spectrum of biological and pharmacological 
activity due to the presence of nitrogen and sulfur which is considered to be 
responsible for the structural features to impart their activities. 
 
Despite an optimal use of available antidiabetic drugs (ADDs), many patients 
fail to experience therapeutic efficacy and others do so only at the expense of 
significant failure in reduction of elevated blood sugar level and toxic side effects. 
The limitations with the conventional ADDs highlighted the need for developing 
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newer antidiabetic agents with less toxic and more effective drugs are required. 
Thiazolidinones are five membered ring system containing sulphur and nitrogen atom, 
received a much attention of medicinal chemists due to their potential biological 
activities. Substituent’s’ at C-4 position of 4-thiazolidinone moiety results in potent α-
amylase inhibitory activity. Prompted by these reports, we aimed to prepare the 
following series of novel 4-thiazolidinone derivatives as potent α-amylase inhibiting 
agents.  
 
Hence the specific aims & objectives of the present study are 
 To synthesize a series of novel 4- thiazolidinones. 
 To characterize the synthesized compounds by IR, NMR, Mass spectra and   
elemental analysis. 
 To evaluate the test compounds for its in vitro α-amylase inhibitory activity. 
 The title compounds are planned to synthesize by using the following synthetic 
routes mentioned in the following schemes.   
Scheme 
Synthesis of 2-(4-substituted phenyl)-3-(4,6-dimethylpyrimidin-2-yl)thiazolidin-
4-one (T1-T5). 
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CHAPTER–4 
4.1. EXPERIMENTAL WORK 
4.1.1 MATERIALS AND METHOD 
Melting points (mp) were taken in open capillaries on thomas hoover melting 
point apparatus and are uncorrected. The IR spectra were recorded in film or in potassium 
bromide disks on a Perkin-Elmer 398 spectrometer. The 1H spectra were recorded on a 
DPX-500 MHz Bruker FT-NMR spectrometer. The chemical shifts were reported as parts 
per million (δ ppm) tetramethylsilane (TMS) as an internal standard. Mass spectra were 
obtained on a JEOL-SX-102 instrument using fast atom bombardment (FAB positive). 
Elemental analysis was performed on a Perkin-Elmer 2400 C, H, N analyzer and values 
were within the acceptable limits of the calculated values. The progress of the reaction 
was monitored on readymade silica gel plates (Merck) using chloroform-methanol (9:1) 
as a solvent system. Iodine was used as a developing agent. Spectral data (IR, NMR and 
mass spectra) confirmed the structures of the synthesized compounds and the purity of 
these compounds was ascertained by microanalysis. Elemental (C, H, N) analysis 
indicated that the calculated and observed values were within the acceptable limits (± 
0.4%). All chemicals and reagents were obtained from Aldrich (USA), or Spectro chem 
Pvt.Ltd (India) and were used without further purification.  
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4.1.1.1. General procedure for synthesis of 2-(4-substituted phenyl)-3-(4,6-
dimethylpyrimidin-2-yl)thiazolidin-4-one (T1-T5). 
4-Thiazolidinones were synthesized in two steps. In the first step, 2-
aminopyrimidine derivatives were synthesized by the reaction of 1,3-dicarbonyl 
compounds with guanidine. Final compounds (T1-T5) were synthesized by the reaction 
of compounds of step 1 with substituted aromatic aldehydes and mercaptoacetic acid, 
using DCC as intramolecular cyclizing agent (Figure 1).  
Step-I: General procedure for the synthesis of 4,6-dimethyl-pyrimidin-2-
ylamine.Equimolar solution of dicarbonyl compounds and guanidine in ethanol was 
refluxed at 78∘C for 8 hr. The reaction mixture was then concentrated to dryness under 
reduced pressure and the residue was partitioned in ethyl acetate. The organic layer was 
successively washed with water and then finally with ether. The organic layer was dried 
over sodium sulphate and the solvent was removed under reduced pressure to get 4,6-
dimethyl-pyrimidin-2-ylamine86. The progress of the reaction was monitored by TLC, 
using methanol in chloroform (2:98) ratio.   
Step-II: General procedure for the synthesis of compounds (T1–T5). A solution 
of 4,6-dimethyl-pyrimidin-2-ylamine (2 mol) and various substituted aldehydes (4 mol) 
was stirred in THF, under ice cold conditions for 5 min, followed by the addition of 
mercaptoacetic acid (3 mol). After 5 min, DCC (2 mol) was added to the reaction mixture 
at 0∘C and the reaction mixture stirred for an additional 5 hr at room temp and filtered. 
The filtrate was concentrated to dryness under reduced pressure and the residue was 
extracted with ethyl acetate. The organic layer was successively washed with 5% aqueous 
citric acid, water, and 5% aqueous sodium hydrogen carbonate and then finally with 
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brine. The organic layer was dried over sodium sulphate and the solvent was removed 
under reduced pressure to get the products87 (T1–T5). The progress of the reaction was 
monitored by TLC, using the solvent system methanol: chloroform (2:98).   
 
4.1.1.2. Synthesis of 2-(4-chlorophenyl)-3-(4, 6-dimethylpyrimidin-2-yl)thiazolidin-4-
one (T1) 
Yield                            : 2.56 g; 77.0 % w/w  
Melting Point               : 216-218 °C 
Rf Value                      : 0.86 (methanol: chloroform (2 :98).  
Molecular Formula      : C15H14ClN3OS  
Molecular Weight        : 319.81(M+), 321(M+2) 
IR (KBr) cm-1                   : 3048 (Ar-CH), 2825 (CH3),1710 (C=O),1597 (C=N Str), 688 (C-
Cl).                                           
1H NMR (CDCl3) δ ppm: 2.35 (s, 3H, CH3), 2.38 (s, 3H, CH3),3.38 (s,1H,CH), 6.86 
(d, J = 8.0 Hz, 1H, Ar-H), 7.00 (d, J =8.0Hz, 2H, Ar-H), 7.15 
(d, J =8.0Hz, 2H, Ar-H).  
Elemental Analysis  
Calculated                  : C, 56.33; H, 4.41; N, 13.14.  
Found                         : C, 56.31; H, 4.41; N, 13.12.  
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4.1.1.3. Synthesis of 2-(4- (dimethylamino) phenyl)- 3- (4,6-dimethylpyrimidin-2-yl) 
thiazolidin-4-one (T2). 
Yield                              : 2.87 g; 83.4 % w/w 
Melting Point                 : 245-247 °C 
Rf Value                        : 0.79 (methanol: chloroform (2 :98).  
Molecular Formula        : C17H20N4OS  
Molecular Weight         : 328.43(M+) 
IR (KBr) cm-1                     : 3085 (Ar-CH), 2948 (CH3),1712 (C=O),1597 (C=NStr),                        
                                        1289(N(CH3)2, 1191 (C-S).                                         
1H NMR (CDCl3) δ ppm: 2.35 (s, 3H, CH3), 2.38 (s, 3H, CH3),2.85(6H, CH3), 3.35   
(s,1H,CH), 6.47 (s, J = 8.0 Hz, 2H, Ar-H), 6.88 (d, J =8.0Hz, 
2H, Ar-H), 6.90 (s, J =8.0Hz, 1H, Ar-H).                                        
Elemental Analysis 
Calculated                   : C, 62.17; H, 6.14; N, 17.06 
Found                          : C, 62.15; H, 6.13; N, 17.04  
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4.1.1.4. Synthesis of 3-(4,6-dimethylpyrimidin-2-yl)-2-(4-vinylphenyl)thiazolidin-4-
one (T3) 
Yield                            : 2.68 g; 77.6 % w/w 
Melting Point               : 238-240 °C 
Rf Value                      : 0.72 (methanol: chloroform (2 :98). 
Molecular Formula      : C17H17N3OS 
Molecular Weight        : 314.4(M+) 
IR (KBr) cm-1                     : 3058 (Ar-CH), 2852 (CH3), 1698 (C=O),1628 (C=N Str), 
                                      (1510) (CH=CH2), 1191 (C-S). 
1H NMR (CDCl3) δ ppm: 2.32 (s, 3H, CH3), 2.36 (s, 3H, CH3), 3.35(s,1H,CH),   
                                      5.62(s,2H, CH2),5.92(s,1H,CH2), 6.63(s,1H,CH),6.47 (s,   
                                      J = 8.0 Hz, 2H, Ar-H), 6.86 (d, J =8.0Hz,1H,Ar-H), 7.00 – 
                                      7.18 (d, J =8.0Hz, 3H, Ar-H). 
  
Elemental Analysis 
Calculated                     : C, 65.57; H, 5.50; N, 13.49. 
Found      : C, 65.55; H, 5.50; N, 13.47. 
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4.1.1.5. Synthesis of 2-(4-hydroxyphenyl)-3-(4,6-dimethylpyrimidin-2-yl)thiazolidin-
4-one (T4). 
Yield                            : 2.66 g; 80.7 % w/w 
Melting Point               : 264-266 °C 
Rf Value                      : 0.78 (methanol: chloroform (2 :98)  
Molecular Formula      : C15H15N3O2S  
Molecular Weight        : 301.36(M+) 
IR (KBr) cm-1                       : 3532 (OH, broad), 3085 (Ar-CH), 2967 (CH3), 1703  
                                       (C=O),1585  (C=N Str), 1191(C-S-C). 
1H NMR (CDCl3) δ ppm:2.35 (s, 3H, CH3), 2.39 (s, 3H, CH3),               
                                         3.35(s,1H,CH),5.00(s,1H,OH),5.92(s,1H,CH2),  
                                        6.61(s,2H,CH),6.86 (d,J=8.0Hz,1H,Ar-H), 
                                        6.81- 6.89 (d, J =8.0Hz, 3H, Ar-H).  
Elemental Analysis 
Calculated                    : C, 59.78; H, 5.02; N, 13.94. 
Found                           : C, 59.76; H, 5.02; N, 13.92. 
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4.1.1.6. Synthesis of 2-(4-aminophenyl)-3-(4,6-dimethylpyrimidin-2-yl)thiazolidin-4-
one (T5) 
Yield                             : 2.93 g; 84.1.0 % w/w. 
Melting Point                : 255-257 °C 
Rf Value                       : 0.81 (methanol: chloroform (2 :98)  
Molecular Formula       : C15H16N4OS 
Molecular Weight        : 300.38(M+) 
IR (KBr) cm-1            : 3383 (NH2), 3076(Ar-CH), 2918 (CH3),  
   1691(C=O), 1597 (C=NStr), 1191 (C-S). 
1H NMR (CDCl3) δ ppm : 2.32 (s, 3H,CH3), 2.37(s,3H,CH3), 3.33(s,1H,CH), 4.0   
  (s,1H,NH2),5.92(s,1H,CH2),6.34(s,2H,CH),6.86  
  (d,J=8.0Hz,1H,Ar- H),6.81-6.89 (d,J =8.0Hz, 3H, Ar-H).  
Elemental Analysis 
Calculated                     : C, 59.98; H, 5.37; N, 18.65. 
Found              : C, 59.97; H, 5.37; N, 18.63. 
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4.2. CHROMATOGRAPHY STUDIES OF SYNTHESIZED COMPOUNDS 
4.2.1 THIN LAYER CHROMATOGRAPHY 
             Thin Layer Chromatography or TLC is a solid-liquid form of chromatography 
here the stationary phase is a polar absorbent and the mobile phase can be a single solvent 
or Combination of solvents. TLC is in expensive technique and quick that can be used for 
determine the number of components in a mixture, verify a substance’s identity, monitor 
the process of a reaction, determine appropriate condition for column chromatography, 
analyze the fractions obtained from column chromatography. 
4.2.1.1 MATERIALS AND METHODS 
1. Preparation of plates 
Silicagel G was mixed in a glass mortar to smooth consistency with the requisite 
amount of water and slurry was quickly transferred to hespreader. The mixtures have 
been spread over the plates in thickness of 0.2mm and allow setting in to a suitable holder 
and after 30minutes; plates were dried at 120oC, for further activation of the absorbent. 
2. Sample application 
        About 2 mm of absorbent from the edge of plate was removed to gives sharply 
defined edges. 2-5µl volumes of synthesized compounds were spotted with the help of 
capillary tubes, just above1cm of the bottom of coated plates. 
3. Development chamber 
           The chromatographic chamber was lined with filter paper dipping in to mobile 
phase so as to maintain the atmospheric saturation with solvent vapors in the chamber. 
The solvent front was allowed to rise to distance of about 12cm from the baseline on the 
plate was removed from the tank and allowed to dry in the air. 
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4. Solvent system 
The choice of best developing solvent is one of the most important decisions in 
practical TLC by review of literature survey on by knowing nature of compounds, this 
solvent system used is (methanol: chloroform (2 :98). 
5. Detection of components 
The spots were visualized under iodine chamber. 
4.2.2 COLUMN CHROMATOGRAPHY 
Purification of synthesized compounds was done by column chromatography. 
Materials  
1.   Glass column ofsize45 cm x3cm. 
2.   Silicagel for column chromatography 60-120 mesh size. 
3.   Eluting solvent system (methanol: chloroform (2 :98).  
Preparation of column 
         The silica gel 60-120 mesh size was made in to slurry with the above solvent 
system. The bottom of the column was plugged with little glass wool. Then the slurry was 
poured in to the column, which is filled with solvent after two third of the column areas 
were filled with slurry. It was set aside for 30 minutes and eluting solvent was passed 
through column for several time ensure good packing of the column. After the adsorbents 
are settled, a filter paper was kept to prevent disturbance of the two player of the 
adsorbent as fresh mobile phase to be added to column for the process of elution. The 
fractions were collected for every 5m land analyzed for the presence of different of 
similar compound by running TLC and then allow evaporating to get the residue. 
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4.3. PHARMACOLOGICAL SCREENING 
4.3.1. ENZYME INHIBITION STUDIES  
DRUGS AND CHEMICALS  
Acarbose (Bicon Ltd, Banglore), porcine pancreatic α-amylase (Sigma-Aldrich, 
USA), Glucose assay kits (Agappe Diagnostics, Kerala) 3, 5-dinitro salicyclic acid 
(HiMedia, Mumbai) and potato starch and maltose (Lobachemie,Mumbai) were 
purchased for the study. All the other chemicals used in the study were of analytical 
grade and were of commercial grade and obtained from respective manufacturers. 
 
IN VITRO ANTIDIABETIC STUDIES 
          In vitro anti-diabetic potential of the synthesized thiazolidinone derivatives were 
studied by performing the enzyme inhibition assay using carbohydrate digestive enzymes 
i.e., α-amylase. 
IN VITRO INHIBITION OF α- AMYLASE 
          The study was carried out with porcine pancreatic α-amylase with starch as 
substrate. Acarbose was selected as the standard drug for comparison of results and 
thiazolidinone derivatives dissolved in water.  
PRINCIPLE87 
             α-amylase digests the starch in reaction mixture to yield maltose. The maltose 
produced would reduce the 3, 5-dinitrosalicyclic acid in the coloring agent to 3 amino 5-
nitrosalicyclicacid. The reaction mixture produced a colour change from orange to red. 
The intensity of red colour will be directly proportional to the amount of maltose 
produced. When an enzyme inhibitor is present in reaction mixture digestion of starch, 
production of maltose and intensity of red colour produced will be less. 
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 PREPARATION OF REAGENTS88-89 
Preparation of Phosphate Buffer 
           Phosphate buffer (20 mM) of pH 6.9 (prepared with sodium phosphate monobasic 
and sodium chloride) 
Preparation of Starch Solution 
           Starch solution (1.0%) prepared with phosphate buffer by boiling. 
Preparation of Coloring Reagents 
          Colouring reagent is prepared by slowly adding sodium potassium tartarate 
solution [prepared in the ratio 12 g of solid dissolved in 8 ml of 2M sodium hydroxide] to 
20 ml of 96 mM 3,5-dinitrosalicyclic acid (prepared in distilled water) and then diluting 
the mixture to 40 ml with distilled water. 
Preparation of enzyme solution 
               Enzyme solution, alpha amylase (0.5 mg/ml) prepared with phosphate buffer 
pH 6.9. 
PROCEDURE
90-92
 
               From 1 mg/ml stock solution different concentration (5-500 µg/ml) of 4-
thiazolodinone derivatives were prepared by adding few drops of dimethyl sulfoxide and 
volume made up with water. About 500 µl of α-amylase (0.5 mg/ml) was added and was 
incubated for 10 minutes at room temperature. Then added 500µl of 1.0% starch solution and 
incubated for another 10 minutes. After that 1 ml of the coloring reagent was added to the 
reaction mixture and heated in a boiling water bath for 5 minutes. After cooling, 10 ml of 
distilled water was added for dilution. To measure the absorbance of the colored extracts, 
blank was prepared for each set of concentration of test sample by replacing the enzyme 
solution with buffer. Control incubations representing 100% enzyme activity was prepared 
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by replacing the test drug with water. The absorbance was then measured at 520 nm. The 
α-amylase inhibition was expressed as percentage of inhibition and the IC50 values 
determined by linear regression plots with varying concentration of synthesized 
thiazolidinone against percentage inhibition.  
CALCULATION OF PERCENTAGE OF INHIBITION: 
 
                 PERCENTAGE INHIBITION =    C-T   x100 
                      C 
Statistical Analysis 
           All values are expressed as mean ± SEM. Data were analyzed by non-parametric      
ANOVA followed by Dunnett’s multiple comparison tests, and other data was evaluated 
using Graph Pad PRISM software. A p-value < 0.05 was considered significantly 
different.  
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CHAPTER– 5 
RESULTS AND DISCUSSION 
5.1. Chemical work: 
           The results of the present work are discussed under the following heads. 
Scheme: 2-(4-substituted phenyl)-3-(4, 6-dimethylpyrimidin-2-yl) thiazolidin-4-one (T1-
T5). 
5.1.1. Synthesis of 2-(4-substituted phenyl)-3-(4,6-dimethylpyrimidin-2-yl)thiazolidin-4-
one.   
 Synthetic route depicted in scheme outline the chemistry part of the present work. 
2-(4-substituted phenyl)-3-(4, 6-dimethylpyrimidin-2-yl)thiazolidin-4-one (T1-T5) were 
obtained by the condensation of dimethyl-pyrimidin-2-ylamine and various substituted 
aldehydes were stirred in THF, followed by the addition of mercaptoacetic acid and 
DCC. The formation of the substituted 4-thiazolidinones were confirmed by the presence 
of characteristic peaks in the IR spectra. It showed characteristic peaks at around 3400 
cm-1 for NH2 stretching  and peak around 2900 cm-1 due to the presence of  N=CH 
stretching. The NMR spectrum of the compounds (T1-T5) showed the characteristic peak 
around δ 2.70 ppm for CH3 group, δ 3.00 ppm for CH2 and δ 5.70 ppm for NCH and also 
shows multiplet in the range of δ 6.80-8.30 ppm owing to aromatic protons. The 
appearance of peak due to chlorine in IR spectra around 700 -800 cm-1 and formation 
M+2 peak in the mass spectra. Data from the elemental analyses and molecular ion 
recorded in the mass spectra further confirmed the assigned structure.  
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5.2. Pharmacological Investigation 
Evaluation of α-amylase inhibitory activity 
 
 All the newly synthesized compounds were screened for in vitro α-amylase 
inhibitory activity at 5, 10, 25, 50, 100, 200, 400, 500µg/ml concentration. Acarbose was 
used as a standard drug in the same concentration. A graded increase in the percentage of 
inhibition was observed with increase in concentration. 
The synthesized compounds in which IC50 of compound-T1 (25 µg/ml) and other 4 
compounds in which IC50 of compounds-T2 (35 µg/ml ) and T5(30µg/ml) showed 
percentage of inhibition closer to that of standard(Acarbose-12 µg/ml). The IC50 values 
of synthesized compounds were found by plotting a graph of percentage inhibition verus 
concentration in µg/ml. The values were compared with that of standard. 
 Among the synthesized compounds, T1 and T5 showed good percentage of 
inhibition at all concentration (5 µg/ml-500 µg). The IC50 values for these compounds 
were found to be 25 µg/ml and 30 µg/ml respectively which are close to IC50 value of 
acarbose (10 µg/ml). T3 and T4 showed moderate α-amylase inhibitory activity at all 
concentrations. The IC50 value for these compounds found to be 59 µg/ml and 110 µg/ml 
respectively.  
        T1 (p-chlorophenyl) produced IC50 value (25 µg/ml) which is relatively less value 
of IC50 indicates the sample has better α-amylase inhibitory activity which has 
significant α-amylase inhibitory activity when compared to that standard.  
        T2 (dimethylamino group) produced IC50 value (35 µg/ml) which is relatively less 
value of IC50 indicates the sample has more α-amylase inhibitory activity which has 
significant α-amylase inhibitory activity when compared to that standard.   
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         T3 (dimethylamino cinnamaldehyde group) produced IC50 value (110 µg/ml) 
which is least value of IC50 indicates the sample has less α-amylase inhibitory activity 
when compared to that standard.   
  T4 (p-hydroxyl group) produced IC50 value (59 µg/ml) which is least value of 
IC50 indicates the sample has less α-amylase inhibitory activity when compared to that 
standard.    
 T5 (p-amino group) produced IC50 value (30 µg /ml) which is relatively less value 
of IC50 indicates the sample has more α-amylase inhibitory activity when compared to 
that standard.    
The best mean IC50 values were achieved with compound (T1, T2, and T5) with 
slight difference among them.   
Among the test compounds, compound 2-(4-chlorophenyl)-3-(4, 6-
dimethylpyrimidin-2-yl)thiazolidin-4-one (T1) was found to be the most active agent 
which showed 88.00 µg/ml α-amylase inhibition in the highest concentration, which have 
p-chloro phenyl group in the 4-thiazolidinone nucleus.  
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PERCENTAGE OF α-AMYLASE INHIBITORY POTENTIAL OF 
SYNTHESISED COMPOUNDS 
IN VITRO α-AMYLASE INHIBITORY ACTIVITY 
 
 
  
 
 
 
Compound 
code 
5 
µg/ml 
10 
µg/ml 
25 
µg/ml 
50 
µg/ml 
100 
µg/ml 
200 
µg/ml 
400 
µg/ml 
500 
µg/ml 
IC50 
µg/ml 
T1 33.75 41.25 54.50 60.41 65.00 75.00 85.00 88.00 25 
T2 29.16 40.46 44.83 49.25 64.16 67.33 78.75 81.58 35 
T3 19.16 28.83 42.79 42.75 49.85 58.75 73.58 79.00 110 
T4 24.54 30.58 35.75 42.16 57.67 60.46 71.16 79.06 59 
T5 30.69 35.47 46.81 56.25 68.75 77.50 80.16 85.40 30 
Standard 
(Acarbose) 27.28 46.17 52.05 63.34 73.11 79.24 82.21 94.01 12 
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CHAPTER– 6 
SUMMARY AND CONCLUSION 
In summary, a new series of 2-(4-substituted phenyl)-3-(4, 6-dimethylpyrimidin-2-
yl) thiazolidin-4-one (T1-T5).were synthesized. These title compounds containing five 
different substituent’s at C-4 position were screened for their α-amylase inhibitory 
activity. Most of the test compounds were found to exhibit significant α-amylase 
inhibitory activity in the lowest concentration. Among the substituent’s at C-4, p-chloro 
phenyl substituent shows maximum α-amylase enzyme inhibitory potency, while 4-
aminophenyl and 4-dimethylaminophenyl substituent showed equipotent or has little less 
α-amylase inhibitory activity when compared to compound T1, but the dimethylamino 
cinnamldehyde and 4-hydroxy phenyl substituent exhibited least α-amylase inhibitory 
activity when compare to other substituents. The order of activity at C-4 is p-chloro 
phenyl ≥ p-amino phenyl ≥ p-dimethylaminophenyl ≥ 4- hydroxyl phenyl ≥ p- 
dimethylamino cinnamldehyde substituents.                         
        Among the test compounds, compound 2-(4-chlorophenyl)-3-(4, 6-
dimethylpyrimidin-2-yl)thiazolidin-4-one (T1) was found to be the most active agent 
which showed 88.00 µg/ml α-amylase  inhibition in the highest concentration, which 
have p-chloro group in the thiazolidinone nucleus.  
Hence this molecule can be selected as a lead molecule of the present study for further 
exploitation.   
  
 
7. FUTURE PLAN OF WORK 
J.K.K.NATTRAJA COLLEGE OF PHARMACY Page 67 
CHAPTER– 7 
FUTURE PLAN OF WORK 
 It may conclude that further beneficial pharmacophore modifications in the design 
of novel 4-thiazolidinone derivatives may be synthesized by designing novel ligands for 
therapeutic target by substituting different functional group and also examine with the 
help of NMR and X-ray which provide three dimensional frame works which can analyze 
structure activity data and can guide the design and synthesis of future potential 
therapeutic drugs towards other chronic disorders. 
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